Anne-Laure Joly
Cell Therapy Development & Analyses, Scientific Lead NEOGAP Therapeutics AB
Seminars
Wednesday 18th November 2026
Balancing Process Flexibility & Standardization While Preserving Antigen Specificity
4:40 pm
- Optimizing manufacturing processes to increase cell dose and scalability while maintaining antigen specificity, functionality, and product quality throughout clinical development
- Ensuring product comparability as manufacturing processes evolve from early clinical studies to larger trials without compromising the biological characteristics that drive therapeutic activity
- Reducing regulatory and scale-up risk by establishing robust, reproducible manufacturing strategies that support both clinical expansion and future commercial readiness
